Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| BIONTECH | 11 | 13 | +4,55 % | ||
| MODERNA | 6 | 16 | +0,51 % | ||
| COMPASS PATHWAYS | 6 | 11 | +0,62 % | ||
| GILEAD SCIENCES | 5 | 5 | -1,77 % | ||
| BIOAGE LABS | 5 | - | -1,82 % | ||
| LEGEND BIOTECH | 4 | - | +0,93 % | ||
| INCYTE | 3 | 25 | -0,73 % | ||
| DISC MEDICINE | 3 | 7 | -2,23 % | ||
| REVOLUTION MEDICINES | 3 | 5 | +1,93 % | ||
| ANAPTYSBIO | 3 | 2 | +5,79 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18:35 | Trader-Interview: Meine Einschätzungen zu SAP, BASF, MARVELL, ATAIBECKLEY, ... | 6 | stock3.com | ||
| 18:10 | 3 Reasons Growth Investors Will Love Neurocrine (NBIX) | 1 | Zacks | ||
| 18:10 | Is Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think "Yes" | 1 | Zacks | ||
| 18:10 | Psychedelika vor Durchbruch: Kurssprung bei Compass Pathways und ein starkes Signal für TEQ Capital | Mike Judith | |||
| 17:46 | Revolution Medicines präsentiert Phase-3-Daten zu Bauchspeicheldrüsenkrebs auf ASCO-Jahrestagung | 3 | Investing.com Deutsch | ||
| 17:46 | BioAge says early data suggest 'best-in-class' potential for inflammation drug | 1 | BioPharma Dive | ||
| 17:42 | Revolution Medicines to present phase 3 pancreatic cancer data at ASCO | 1 | Investing.com | ||
| 17:30 | Revolution Medicines, Inc.: Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 17:26 | Tempus AI Inc. (TEM): Nancy Pelosi Likes This AI-Powered Medicine Company | 5 | Insider Monkey | ||
| 17:18 | BioAge Labs Stock Gains After Positive Early Data And Pipeline Plans | 1 | Benzinga.com | ||
| 17:10 | BIIB Inks Deal to Acquire Rights to Felzartamab in China, Stock Up | 2 | Zacks | ||
| 16:54 | RBC Capital reiterates Exelixis stock rating on competitive position | 5 | Investing.com | ||
| 16:54 | Regeneron submits U.S. application for gMG treatment cemdisiran | 2 | Investing.com | ||
| 16:42 | IDEAYA to present trial data at ASCO meeting in June | 2 | Investing.com | ||
| 16:42 | Black Diamond Therapeutics, Inc: Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 16:38 | Eilmeldung am Abend: BIONTECH SE ADR zündet Kursrakete! | 134 | Maximilian Berger | ||
| 16:36 | Regeneron Pharmaceuticals, Inc.: Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial | 3 | GlobeNewswire (USA) | ||
| 16:36 | Moderna granted EU nod for combined COVID-19 and flu vaccine | 8 | Seeking Alpha | ||
| 16:36 | Bicycle Therapeutics plc: Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting | 188 | Business Wire | Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced... ► Artikel lesen | |
| 16:35 | Jazz Pharmaceuticals Stock, a Barchart Favorite, Trends Higher as Trump Renews Cannabis Hopes. Should You Buy JAZZ Here? | 2 | Barchart.com |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.